If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
|Articles|October 1, 2007
- Volume 0 0
Seven Deadly Sins AND HOW TO AVOID THEM: Interviews
Advertisement
- ARRIVING LATE?Set 2 alarm clocks, and allow more than enough travel time.
- DRESSING INFORMALLY?Have a dry-cleaned, conservative business suit ready to go.
- POOR EYE CONTACT?Concentrate on maintaining eye contact throughout the interview. Eye contact is not the same asstaring.
- ASKING ONLY SELF-SERVING QUESTIONS?Prepare questions that show your interest in the position or company.
- DEMONSTRATING IGNORANCE ABOUT THE HIRING COMPANY?Do some background research on the companybefore the interview.
- USING EVERYDAY LANGUAGE AND SPEECH PATTERNS?Practice interviewing and using professional terminologywhere appropriate. Avoid ?like,? ?ya know,? ?really,? and ?OK?? when they are simply fillers.
- FAILING TO ADDRESS THE QUESTION ASKED?Be careful to listen to the question and understand it before answering.
Articles in this issue
about 19 years ago
PRUITT-SCHUTTE COMPETITION STRIVES FOR EXCELLENCEabout 19 years ago
DOCTOR TOM'S TOP TEN TIPS: PASSING THE PHARMACY BOARDSabout 19 years ago
PHARMACY GROUPS JOIN TOGETHER TO IMPROVE SERVICEabout 19 years ago
STUDENT POLITICAL INVOLVEMENT DOES IMPACT PHARMACYabout 19 years ago
Seven Deadly Sins AND HOW TO AVOID THEM: R?sum?about 19 years ago
OWNING YOUR OWN PHARMACY: A PLAN AND PARTNERSHIP COME TOGETHERabout 19 years ago
TECHNOLOGY EXPANDS PHARMACY REACH IN UNDERSERVED RURAL AREASabout 19 years ago
PARTNERSHIP PROGRAMS?A WIN-WIN FOR COMMUNITY PHARMACISTSabout 19 years ago
GOOD NEIGHBOR PHARMACY REWARDS EXCELLENCEabout 19 years ago
WELCOME TO INDEPENDENT PHARMACYAdvertisement
Related to this article
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice
5